This means that scientists who believed they were publishing data on the efficacy of experimental drugs on one type of cancer were actually using cells from another.

FORBES: What Do The War On Cancer And Climate Modeling Have In Common?

Merck is pouring tens of millions into an experimental treatment for a new type of Alzheimer's drug meant to limit the main ingredient in the brain-damaging plaques believed to cause the disease.

WSJ: CEO: Risks key for Merck to succeed, help patients